Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.
<h4>Background and objectives</h4>Tissue inhibitor of metalloproteinase-2 (TIMP-2) is a small secretory glycoprotein with anti-matrix metalloproteinase activity. Data on the value of TIMP-2 as a prognostic factor in non-small cell lung cancer (NSCLC) are discordant and remain controversi...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0124230 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849320787651067904 |
|---|---|
| author | Lin Zhu Hong Yu Shi-Yuan Liu Xiang-Sheng Xiao Wei-Hua Dong Yi-Nan Chen Wei Xu Tong Zhu |
| author_facet | Lin Zhu Hong Yu Shi-Yuan Liu Xiang-Sheng Xiao Wei-Hua Dong Yi-Nan Chen Wei Xu Tong Zhu |
| author_sort | Lin Zhu |
| collection | DOAJ |
| description | <h4>Background and objectives</h4>Tissue inhibitor of metalloproteinase-2 (TIMP-2) is a small secretory glycoprotein with anti-matrix metalloproteinase activity. Data on the value of TIMP-2 as a prognostic factor in non-small cell lung cancer (NSCLC) are discordant and remain controversial. A systematic review and meta-analysis was performed to explore this issue.<h4>Methods</h4>We identified the relevant literature by searching the PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure, SinoMed, and Wanfang Data databases (search terms: "non-small cell lung cancer" or "NSCLC" or "Lung Carcinoma, Non-Small-Cell", "Tissue Inhibitor of Metalloproteinase-2" or "TIMP-2", and "prognosis" or "prognostic" or "survive") for updates prior to March 1, 2014. The pooled hazard ratio (HR) of overall survival with a 95% confidence interval (95% CI) was used to evaluate the strength of the association between positive TIMP-2 expression and survival in patients with NSCLC.<h4>Results</h4>We included 12 studies in our systematic review; five studies involving 399 patients with NSCLC were meta-analyzed. The pooled HR of all included patients was 0.57 (95% CI: 0.43-0.77), and the HRs of subgroup analysis according to stage (I-IV), testing method (immunohistochemistry) and high TIMP-2 expression percentage (<50%) were 0.63 (95% CI: 0.43-0.92), 0.55 (95% CI: 0.41-0.74), and 0.50 (95% CI: 0.28-0.88), respectively. These data suggested that high TIMP-2 expression is associated with favorable prognosis in NSCLC. The meta-analysis did not reveal heterogeneity or publication bias.<h4>Conclusions</h4>TIMP-2 expression indicates favorable prognosis in patients with NSCLC; as a protective factor, it could help predict outcome and may guide clinical therapy in the future. |
| format | Article |
| id | doaj-art-0ad8d81d9dac4d94a96d87ae87366f66 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-0ad8d81d9dac4d94a96d87ae87366f662025-08-20T03:49:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012423010.1371/journal.pone.0124230Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.Lin ZhuHong YuShi-Yuan LiuXiang-Sheng XiaoWei-Hua DongYi-Nan ChenWei XuTong Zhu<h4>Background and objectives</h4>Tissue inhibitor of metalloproteinase-2 (TIMP-2) is a small secretory glycoprotein with anti-matrix metalloproteinase activity. Data on the value of TIMP-2 as a prognostic factor in non-small cell lung cancer (NSCLC) are discordant and remain controversial. A systematic review and meta-analysis was performed to explore this issue.<h4>Methods</h4>We identified the relevant literature by searching the PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure, SinoMed, and Wanfang Data databases (search terms: "non-small cell lung cancer" or "NSCLC" or "Lung Carcinoma, Non-Small-Cell", "Tissue Inhibitor of Metalloproteinase-2" or "TIMP-2", and "prognosis" or "prognostic" or "survive") for updates prior to March 1, 2014. The pooled hazard ratio (HR) of overall survival with a 95% confidence interval (95% CI) was used to evaluate the strength of the association between positive TIMP-2 expression and survival in patients with NSCLC.<h4>Results</h4>We included 12 studies in our systematic review; five studies involving 399 patients with NSCLC were meta-analyzed. The pooled HR of all included patients was 0.57 (95% CI: 0.43-0.77), and the HRs of subgroup analysis according to stage (I-IV), testing method (immunohistochemistry) and high TIMP-2 expression percentage (<50%) were 0.63 (95% CI: 0.43-0.92), 0.55 (95% CI: 0.41-0.74), and 0.50 (95% CI: 0.28-0.88), respectively. These data suggested that high TIMP-2 expression is associated with favorable prognosis in NSCLC. The meta-analysis did not reveal heterogeneity or publication bias.<h4>Conclusions</h4>TIMP-2 expression indicates favorable prognosis in patients with NSCLC; as a protective factor, it could help predict outcome and may guide clinical therapy in the future.https://doi.org/10.1371/journal.pone.0124230 |
| spellingShingle | Lin Zhu Hong Yu Shi-Yuan Liu Xiang-Sheng Xiao Wei-Hua Dong Yi-Nan Chen Wei Xu Tong Zhu Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE |
| title | Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. |
| title_full | Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. |
| title_fullStr | Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. |
| title_full_unstemmed | Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. |
| title_short | Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. |
| title_sort | prognostic value of tissue inhibitor of metalloproteinase 2 expression in patients with non small cell lung cancer a systematic review and meta analysis |
| url | https://doi.org/10.1371/journal.pone.0124230 |
| work_keys_str_mv | AT linzhu prognosticvalueoftissueinhibitorofmetalloproteinase2expressioninpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT hongyu prognosticvalueoftissueinhibitorofmetalloproteinase2expressioninpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT shiyuanliu prognosticvalueoftissueinhibitorofmetalloproteinase2expressioninpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT xiangshengxiao prognosticvalueoftissueinhibitorofmetalloproteinase2expressioninpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT weihuadong prognosticvalueoftissueinhibitorofmetalloproteinase2expressioninpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT yinanchen prognosticvalueoftissueinhibitorofmetalloproteinase2expressioninpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT weixu prognosticvalueoftissueinhibitorofmetalloproteinase2expressioninpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT tongzhu prognosticvalueoftissueinhibitorofmetalloproteinase2expressioninpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis |